ONCOLOGY Vol 37, Issue 12
Impact of Sotorasib and Adagrasib in KRAS G12C–Mutated NSCLC
December 27th 2023ArticleInterview
“KRAS is probably the most exciting area in clinical trials right now, not only in thoracic oncology but also pancreatic and colorectal cancer, where we’ve seen a lot of combination therapies. My view is the small molecule inhibitors are the base, not the ceiling.”
Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review
Sangam Shah, MBBS;Rukesh Yadav, MBBS;Abhinav Bhattarai, BSc;Sunraj Tharu, BSc;Prakash Sharma, MBBS;Prativa Subedi, MBBS;Arun Kharel, MBBS;Pitambar Khanal, MBBS;Pradeep Khanal, MBBS, MD;Sri Kollepara, MD;Krishna Gundabolu, MBBS, MS
December 18th 2023ArticleReview Article
Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.
Suneel D. Kamath, MD;Joanna Roopkumar, MD;Ying Ni, PhD;Minqian Shen, MD, PhD;Pablo Bejarano, MD;Daniela Allende, MD;Arun Nagarajan, MD;Tim Nguyen, MD;Bachar Dergham, MD;Dale Shepard, MD, PhD;Marc A. Shapiro, MD;Michael J. McNamara, MD;Bassam N. Estfan, MD;Kanika G. Nair, MD;Alok A. Khorana, MD
December 15th 2023ArticleOriginal Research
Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
